How I work to improve patient health outcomes at a national level at NHS RightCare

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e19104-e19104
Author(s):  
Tom Bregartner

e19104 Background: The Validation Model is an educational series built on the concept of strengthening education by incorporating the patient perspective. After conducting two iterations of the Validation Model to educate oncologists in the treatment of NSCLC, Quintiles Medical Education was able to demonstrate that CME can lead to improved patient health outcomes by changing physician behaviors in practice. Educational measurement tools, including chart audits, revealed an increase in tumor histology and EGFR mutation testing. Histologic and molecular marker testing leads to optimization of treatment based on tumor pathology and genotype, respectively, as per NCCN guidelines. Personalization of treatment according to guidelines results in improved health outcomes. Methods: The Validation Model consisted of 6 educational activities for which efficacy was measured by conducting pre- and post-tests of knowledge and clinical competence among participants. Participants were then asked to complete a follow-up survey which was designed to determine if specific practices had been implemented since participation. The self-self reported behavioral data was validated by the distribution of patient surveys, designed to measure patient satisfaction and expectation with care, and chart audits, designed to determine the actual practice habits of the participating practitioners. Results: More than 500 participants have completed all 6 of the educational activities. The activities have demonstrated improved knowledge and competence in the educational setting and changes to clinical practice and, as a result, patient health outcomes. Conclusions: CME can be used as an effective tool to improve patient health outcomes in the treatment of NSCLC.


2016 ◽  
Vol 41 (3) ◽  
pp. 191-195 ◽  
Author(s):  
Victoria M. Rizzo ◽  
Jeannine M. Rowe ◽  
Gayle Shier Kricke ◽  
Kate Krajci ◽  
Robyn Golden

2021 ◽  
Vol 10 (22) ◽  
pp. 5284
Author(s):  
Michael Feehan ◽  
Leah A. Owen ◽  
Ian M. McKinnon ◽  
Margaret M. DeAngelis

The use of artificial intelligence (AI) and machine learning (ML) in clinical care offers great promise to improve patient health outcomes and reduce health inequity across patient populations. However, inherent biases in these applications, and the subsequent potential risk of harm can limit current use. Multi-modal workflows designed to minimize these limitations in the development, implementation, and evaluation of ML systems in real-world settings are needed to improve efficacy while reducing bias and the risk of potential harms. Comprehensive consideration of rapidly evolving AI technologies and the inherent risks of bias, the expanding volume and nature of data sources, and the evolving regulatory landscapes, can contribute meaningfully to the development of AI-enhanced clinical decision making and the reduction in health inequity.


2020 ◽  
Vol 35 (7) ◽  
pp. 292-294
Author(s):  
Shane Jackson

In early 2019, a report from Australia documented significant data about the harms associated with medication use. This editorial reports on the Australian government's changes to cycles-of-care and telehealth reviews, changes made to improve patient health outcomes, and payment to pharmacists—information that may be useful to other countries.


Author(s):  
Véronique Nabelsi

Healthcare organizations in many countries are compelled to pursue drastic supply cost reductions, while continuing to improve patient health outcomes, as they must meet ever increasing economic and performance pressures brought on by changes in national health policies. As demonstrated in many other industries, these improvements require more integrated Supply Chain Management (SCM) practices, processes, and systems. The author develops a strategic framework for Customer-Oriented or Patient-Driven SCM, integrating the evolving economics of the healthcare industry and the emerging dynamics of global supply chains. The chapter focuses on modern SCM approaches such as agile and lean supply chains, in order to efficiently realign hospitals and their Material Management Systems (MMS) on patient health outcomes.


2020 ◽  
Vol 34 (1) ◽  
pp. 26-28
Author(s):  
Mike Lapaine

Healthcare institutions have for some time pursued the Triple Aim: improve patient health outcomes, improve patient experience, and reduce costs. More recently, it has been recognized that the “missing piece” of success is to improve the experience of their clinicians in order to improve the three aims. The leadership of Bluewater Health has been using the Quadruple Aim since 2016 and, by working to improve employee engagement, has succeeded in also delivering exemplary care that has improved patient outcomes and experience and reduced costs.


2020 ◽  
Vol 35 (7) ◽  
pp. 292-294
Author(s):  
Shane Jackson

In early 2019, a report from Australia documented significant data about the harms associated with medication use. This editorial reports on the Australian government's changes to cycles-of-care and telehealth reviews, changes made to improve patient health outcomes, and payment to pharmacists—information that may be useful to other countries.


2012 ◽  
Vol 29 (1) ◽  
pp. 101-109 ◽  
Author(s):  
Koonal Kirit Shah ◽  
Jorge Mestre-Ferrandiz ◽  
Adrian Towse ◽  
Emily Nash Smyth

Pharmaceutical manufacturers, regulators, patients, providers, and payers all have a shared interest in improving health outcomes for patients with cancer. Each plays an important role in helping to achieve this common goal. Pharmaceutical manufacturers seek to develop new medicines that are supported by robust and clinically meaningful evidence of their safety, efficacy, and effectiveness. Regulators authorize these medicines based on evaluations of their safety and efficacy. Patients and providers together make treatment decisions and desire access to the most effective treatment options. Payers appraise new medicines with the goal of ensuring access to those medicines that constitute efficient uses of healthcare expenditure. Profits generated from the sale of the medicines provide a return to the manufacturer, which helps to drive continued research and development in an effort to improve patient health outcomes and societal well-being. Many payers have initiated health technology assessment (HTA) activities to inform decision making in light of the rising costs of health care. Given the financial constraints imposed as a result of the global economic crisis, HTAs are likely to become increasingly important as payers seek value for money solutions to major health problems. Successful collaboration and aligning incentives across stakeholders is critical to ensuring that patients are able to access the most effective medicines.


2012 ◽  
pp. 1418-1436
Author(s):  
Véronique Nabelsi

Healthcare organizations in many countries are compelled to pursue drastic supply cost reductions, while continuing to improve patient health outcomes, as they must meet ever increasing economic and performance pressures brought on by changes in national health policies. As demonstrated in many other industries, these improvements require more integrated Supply Chain Management (SCM) practices, processes, and systems. The author develops a strategic framework for Customer-Oriented or Patient-Driven SCM, integrating the evolving economics of the healthcare industry and the emerging dynamics of global supply chains. The chapter focuses on modern SCM approaches such as agile and lean supply chains, in order to efficiently realign hospitals and their Material Management Systems (MMS) on patient health outcomes.


Sign in / Sign up

Export Citation Format

Share Document